MUNICH, March 18, 2020
The Winterlight Labs speech assessment will be used by Vivoryon Therapeutics in their Phase 2b Alzheimer’s clinical trial.
Vivoryon has also added exploratory parameters selected with the rationale of advancing less invasive diagnostic technologies. This will include the Winterlight Labs speech assessment, the use of EEG to test neuronal network activity and connectivity, as well as a set of blood-based biomarkers run by Nordic Bioscience. The inclusion of these parameters will further strengthen PQ912's data package and introduce more innovative and less demanding diagnostic tools to future patients.
The inclusion of speech-based biomarkers in clinical trials provides a time- and cost-efficient method of tracking patients’ cognitive status and response to therapy. Winterlight is pleased to provide Vivoryon with a sensitive, non-invasive assessment to aid their development of a novel therapy for early AD.
Winterlight Labs is commercializing a proprietary language-based diagnostic system that analyzes natural speech to detect and monitor dementia, Alzheimer’s, aphasia, and various other cognitive conditions. Winterlight's scalable platform uses short recorded speech samples to analyze hundreds of linguistic cues, and can detect dementia and other conditions with a high level of accuracy. This is a major improvement over current pencil-and-paper tests which are time-consuming, costly, and difficult to administer. The platform has applications in drug trials, long-term and primary care, and speech-language pathology.
Since its founding, Winterlight Labs has seen strong interest from pharmaceutical companies and other potential partners who view the technology as a major improvement over current methods of detection or screening. The company has gained support from the pan-Canadian AGE-WELL Network of Centres of Excellence (NCE), the Ontario Brain Institute, Ontario Centres of Excellence, and the University of Toronto Banting and Best Centre for Innovation and Entrepreneurship. For more information, visit www.winterlightlabs.com.
Media Inquiries:
Winterlight Labs
Liam Kaufman, CEO
liam [at] winterlightlabs.com